FITT-VP Principles, Progression & Prescription Foundations

ACSM Certified Clinical Exercise Physiologist ACSM-CEP

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 The ACSM-CEP Role, Job Definition & Scope of Practice 1.2 Exam Format, Domain Weights & Scoring 1.3 Eligibility, Study Planning & Test-Day Strategy

2 Applied Exercise Physiology & Metabolic Calculations

Bioenergetics & Energy Systems (ATP-PC, glycolytic, oxidative) Acute Cardiorespiratory & Metabolic Responses to Aerobic Exercise Responses to Resistance Exercise & Chronic Training Adaptations ACSM Metabolic Equations, METs & Interpreting VO₂ / RER / Ventilatory Threshold

3 Pathophysiology of Clinical Populations

3.1 Coronary Artery Disease, Myocardial Infarction & Revascularization (PCI/CABG) 3.2 Heart Failure, Valvular Disease & Cardiac Rhythm Disorders 3.3 Hypertension, Dyslipidemia & Peripheral Artery Disease 3.4 Pulmonary Disease: COPD, Asthma & Restrictive/Interstitial Disorders 3.5 Diabetes, Metabolic Syndrome & Obesity 3.6 Renal Disease & Musculoskeletal/Orthopedic Conditions 3.7 Neuromuscular, Neurological & Cognitive Conditions (stroke, MS, Parkinson's, SCI) 3.8 Neoplastic, Immunologic & Hematologic Disorders (cancer, HIV/AIDS, anemia)

4 Clinical ECG Interpretation

4.1 ECG Leads, Waveforms, Rate & Rhythm Determination 4.2 Arrhythmias & Conduction Blocks 4.3 Ischemia, Injury & Infarction (ST changes, exercise-induced) 4.4 Drug & Electrolyte ECG Effects; Resting/Exercise Monitoring Setup & Lead Placement

5 Pharmacology for the Clinical Exercise Physiologist

5.1 Beta-Blockers, Calcium-Channel Blockers & Nitrates 5.2 RAAS Agents, Diuretics, Antiarrhythmics, Lipid-Lowering & Antithrombotic Drugs 5.3 Bronchodilators, Corticosteroids, Insulin & Oral Antidiabetic Agents 5.4 Medication Effects on HR/BP & Exercise Response; Dose/Meal/Dialysis Timing

6 Patient Assessment (Domain I, 18%)

6.1 Medical Records, HIPAA/HITRUST, Charting & Physician Referral 6.2 Patient Interview, Medical History & Medication Reconciliation 6.3 Resting Vital Signs, Body Composition & Resting ECG 6.4 Preparticipation Health Screening & Level of Monitoring (PAR-Q+, ACSM algorithm, ACC/AHA · GOLD · ADA · AACVPR) 6.5 Assessing Patient Goals, Readiness & Psychosocial Status

7 Clinical Exercise Testing (Domain II, 18%)

Submaximal Aerobic Tests (treadmill, cycle, step, 6-minute walk) Musculoskeletal Fitness, Mobility & Balance Testing Maximal Symptom-Limited GXT: Protocols, Contraindications & ECG Prep Test Termination: Relative & Absolute Indications Interpreting & Reporting Results (ECG response, RPP, claudication, Duke Treadmill Score, VO₂/RER/AT)

8 Exercise Prescription for Clinical Populations (Domain III, 22%)

FITT-VP Principles, Progression & Prescription Foundations Ex Rx for Cardiovascular Disease (CAD, HF, HTN, PAD, post-revascularization) Ex Rx for Pulmonary Disease (COPD, asthma; breathing techniques, supplemental O2) Ex Rx for Diabetes, Metabolic Syndrome & Obesity Ex Rx for Musculoskeletal, Neuromuscular, Neoplastic & Other Conditions Communicating Intensity (THR, RPE, talk test), Monitoring & Modifying the Prescription

9 Exercise Training & Leadership (Domain IV, 24%)

9.1 Discussing the Training Plan, Clinician & Patient Expectations/Goals 9.2 Instructing & Modifying Exercise Modes (cardiorespiratory, strength/endurance, flexibility, coordination, agility) 9.3 Patient Monitoring & Supervision During Exercise (telemetry, oximetry, glucometry, ECG) 9.4 Contraindications to Training & Modifying Recommendations 9.5 Documenting Clinical Status, Reporting Adverse Events & Interdisciplinary Coordination

10 Education & Behavior Change (Domain V, 13%)

10.1 Behavioral-Health Screening & Recognizing Distress (PHQ-9, Beck, SF-36; referral) 10.2 Patient Education, Health Literacy & Disease Self-Management 10.3 Motivational Interviewing & Behavior-Change Theories (Transtheoretical, HBM, Social Cognitive, Five-A's) 10.4 Promoting Adherence, Self-Efficacy, Relapse Prevention & Social Support

11 Legal, Professional & Emergency Management (Domain VI, 5%)

11.1 Emergency Equipment, Crash Cart Inspection & Emergency Procedures 11.2 CPR/AED/BLS/ACLS, Universal Precautions & EMS Activation 11.3 Scope of Practice, Legal/Ethical Standards, Liability/Negligence, Informed Consent & Professional Organizations (ACSM/AACVPR/AHA)

FITT-VP Principles, Progression & Prescription Foundations

Key Takeaways Explain This Topic AI

FITT-VP stands for Frequency, Intensity, Time, Type, Volume, and Progression, and every prescription must be anchored to GXT and assessment findings, not population formulas.

Baseline aerobic targets are 3-5 days/week, 40-59% HRR (moderate) to 60-89% HRR (vigorous), 20-60 minutes, with a weekly volume goal of 500-1,000 MET-minutes.

Karvonen's formula (THR = [(HRmax - HRrest) x %intensity] + HRrest) is the standard %HRR intensity calculation tested on the exam.

Clinical progression follows 'start low, go slow': increase duration first, then frequency, and advance intensity last and most cautiously.

When HR-based methods are unreliable (beta-blockers, chronotropic incompetence, arrhythmia), RPE or ventilatory-threshold-based prescription replaces %HRR or %HRmax.

Last updated: July 2026

The FITT-VP Framework

Every individualized exercise prescription a Clinical Exercise Physiologist (CEP) writes is organized around FITT-VP : Frequency, Intensity, Time, Type, Volume, and Progression . FITT-VP is not a generic template pulled off a shelf — it is anchored to the findings of the patient's assessment (Domain I) and exercise test (Domain II), including any ischemic threshold, ventilatory threshold, orthopedic limitation, or medication effect uncovered during testing. A prescription that ignores those findings and simply applies an age-predicted formula can push a clinical patient above a safe threshold.

Aerobic (Cardiorespiratory) FITT-VP

For most clinical populations, ACSM's baseline aerobic targets are:

Frequency: 3–5 days/week (up to most days of the week using shorter bouts for higher-risk or severely deconditioned patients)

Intensity: moderate (40–59% heart rate reserve [HRR] or VO2 reserve [VO2R]; RPE 12–13 on the 6–20 Borg scale) progressing toward vigorous (60–89% HRR/VO2R; RPE 14–16) as tolerated and as cleared by the referring provider

Time: 20–60 minutes per session, often broken into shorter accumulated bouts (e.g., 5–10 minutes) early in a program

Type: rhythmic, large-muscle-group activities (walking, cycling, stepping, aquatic exercise)

Volume: a weekly target, commonly expressed as 500–1,000 MET-minutes/week or roughly 150–300 minutes/week of moderate-intensity activity

Resistance and Flexibility FITT-VP

Resistance training for deconditioned or clinical patients typically starts conservatively: 2–3 non-consecutive days/week, 1–3 sets of 10–15 repetitions per major muscle group at an intensity corresponding to RPE 11–13 ("fairly light" to "somewhat hard") or roughly 40–60% of one-repetition maximum (1RM) for novice/clinical starters, progressing toward 60–80% 1RM as tolerance and physician clearance allow. Flexibility training is prescribed at least 2–3 days/week, holding a static stretch to the point of mild tightness (not pain) for 10–30 seconds, repeated 2–4 times per muscle group, with a weekly volume target of about 60 seconds of total stretch time per muscle group.

Volume and Progression

Volume is the product of frequency, intensity, and time, and it is what actually predicts the dose-response health benefit — two prescriptions with different combinations of F, I, and T can deliver the same weekly volume. Progression in clinical populations follows a "start low, go slow" principle: increase duration (Time) first, in 5–10 minute increments, before increasing Frequency , and increase Intensity last and only once the patient tolerates the current volume without abnormal signs or symptoms. Progressing intensity too early is the most common way a clinical exercise prescription becomes unsafe.

Methods of Prescribing Intensity

Method How it works Best used when

%HRR (Karvonen) THR = [(HRmax − HRrest) × %intensity] + HRrest GXT-derived HRmax is available and heart rate response is normal

%HRmax Target = HRmax × %intensity (no resting HR adjustment) Simple estimate; less precise correlate to %VO2R than %HRR

%VO2R Similar construct to %HRR but anchored to measured VO2 Metabolic (gas-exchange) data from the GXT is available

RPE (Borg 6–20 or CR10) Patient self-rates perceived effort Medications (beta-blockers), pacemakers, or chronotropic incompetence blunt HR response

METs Absolute intensity relative to resting metabolic rate Comparing workloads across activities/settings

Ventilatory threshold (VT1/VT2) Individualized breakpoints from expired gas analysis Highest precision; preferred in cardiac/pulmonary patients when available

The Karvonen (%HRR) method is the calculation most commonly tested on the exam. For a patient with an HRmax of 160 bpm and resting HR of 70 bpm, a 50% HRR target heart rate is calculated as (160 − 70) × 0.50 + 70 = 115 bpm.

Age-predicted HRmax formulas (e.g., 220 − age) are discouraged in clinical prescription because they carry wide individual error and do not account for cardiac medications. Whenever a symptom-limited GXT has been performed, the CEP should prescribe from the measured HRmax and any ischemic or ventilatory threshold identified on that test — not from a population estimate. When HR-based methods are unreliable (beta-blockade, atrial fibrillation, paced rhythm, autonomic neuropathy), RPE or the talk test becomes the primary intensity tool, discussed further in Section 8.6.

Worked Volume Example

Volume can also be checked in MET-minutes/week, which lets the CEP compare very different-looking prescriptions on an equal footing. A 30-minute walk five days a week at 3.5 METs yields 30 × 5 × 3.5 = 525 MET-minutes/week — inside the 500–1,000 MET-minute target band even though the session length looks modest. This calculation matters on the exam because two prescriptions with different Frequency/Intensity/Time combinations can deliver an equivalent — or very different — weekly training stimulus, and the CEP is expected to reason from total volume, not from any single FITT variable in isolation.

Setting-Specific Considerations

FITT-VP must also be adapted to where the exercise occurs — supervised medical settings (telemetry-monitored cardiac rehab), community programs, home-based programs, or virtual/tele-exercise sessions. Home and virtual settings generally call for more conservative intensity targets, simpler RPE- or talk-test-based monitoring (since HR telemetry is unavailable), and explicit written stop criteria the patient can self-apply, together with SMART (Specific, Measurable, Achievable, Relevant, Time-bound) goals that reflect the setting's monitoring limitations.